Lupus Foundation of America4d
Fate Therapeutics Announces Promising Initial Data from FT819 Phase 1 Study for Moderate to Severe Systemic Lupus Erythematosus
Fate Therapeutics has announced encouraging initial data from the FT819 phase 1 autoimmunity study for people with ...
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and ...
Fate Therapeutics presents new data from FT819 study
Fate Therapeutics (FATE) presented new clinical and translational data from the company’s FT819 Phase 1 Autoimmunity study for ...
Seeking Alpha26d
Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options
Fate Therapeutics, Inc. (NASDAQ:FATE) recently reported positive data from its phase 1 autoimmunity study using FT819 for the treatment of patients with moderate-to-severe Systemic Lupus ...
Yahoo Finance4d
Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue?
Its immuno-oncology pipeline includes iPSC-derived natural killer (NK) cells and T-cell product candidates. A phase I study of FT819, a T-cell product candidate for patients with systemic lupus ...